Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pterygia Conjunctival Diseases Eye Diseases Pterygium

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dr. Schechter

Boynton Beach, Florida, 33426, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

pts with symptomatic pterygia unresponsive to palliative treatment.

Treatment and study plan

Topical Cyclosporine

Drug

Sponsors and collaborators

Lead sponsor

Innovative Medical

Industry

Registry information

Important dates

First posted: Oct 3, 2006
Registry last updated: Feb 13, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed